Nongshim Co. expects to post record instant noodles overseas sales of US$990 million this year, up 24 percent from last year, due to strong pandemic-triggered demand.
According to South Korea's top instant noodle maker, its major overseas subsidiaries in the US and China posted double-digit growth with plants running at full capacity.
The best-sellers are its flagship Shin Ramyun and Chapaguri, a signature noodle dish that was featured in the Oscar-winning film Parasite.
Nongshim expects sales in the US and Canada to reach $326 million this year, increasing 28 percent from last year.
Sales of Shin Ramyun are forecast to reach $120 million in the US.
The company also expects sales in Europe to surge 30 percent this year to $390 million.
Nongshim, the world's fifth-largest instant noodle manufacturer, aims to sell $1.11 billion overseas next year, up 12 percent from 2020.


China’s Ultra-Cheap EV Boom: Why Electric Cars Cost Far Less Than in the U.S.
Apple Q2 2026 Earnings Surge as iPhone 17 Sales Drive Record Revenue
Ford Q1 Earnings Beat Expectations, Stock Surges on Strong Guidance
Microsoft Azure Growth Forecast Beats Expectations Amid Rising AI Competition
Alphabet Earnings Surge on AI Growth, Cloud Revenue, and Strong Search Performance
Novartis Q1 2026 Earnings Miss Expectations as Generic Competition Pressures Sales
Air Liquide Q1 Revenue Misses Estimates Amid Currency and Energy Headwinds
Lightelligence IPO Soars Over 400% in Hong Kong Debut Amid Rising AI Investment Demand
WuXi AppTec Stock Surges on Strong Q1 Earnings and CRDMO Demand Growth
Qualcomm Stock Surges Despite Weak Guidance After Q2 2026 Earnings Beat
Micro Systemation Reports Q1 Loss Amid Strategic Investments and Revenue Growth
Robinhood Q1 Earnings Miss Expectations, Stock Drops After Hours
Samsung Reports Record Profit as AI Boom Drives Memory Chip Demand
Amazon Stock Dips Despite Record Earnings as AI Infrastructure Spending Surges
Pershing Square Raises $5 Billion in Landmark U.S. IPO and Share Placement
AstraZeneca Q1 2026 Earnings Surge on Strong Oncology and Rare Disease Drug Sales 



